Skip to Main content Skip to Navigation
Journal articles

A glycosyltransferase gene signature to detect pancreatic ductal adenocarcinoma patients with poor prognosis

Abstract : Background: Pancreatic ductal adenocarcinoma (PDAC) is characterized by an important heterogeneity, reflected by different clinical outcomes and chemoresistance. During carcinogenesis, tumor cells display aberrant glycosylated structures, synthetized by deregulated glycosyltransferases, supporting the tumor progression. In this study, we aimed to determine whether PDAC could be stratified through their glycosyltransferase expression profiles better than the current binary classification (basal-like and classical) in order to improve detection of patients with poor prognosis. Methods: Bioinformatic analysis of 169 glycosyltransferase RNA sequencing data were performed for 74 patient-derived xenografts (PDX) of resected and unresectable tumors. The Australian cohort of International Cancer Genome Consortium and the microarray dataset from Puleo patient's cohort were used as independent validation datasets. Findings: New PDAC stratification based on glycosyltransferase expression profile allowed to distinguish different groups of patients with distinct clinical outcome (p-value = 0.007). A combination of 19 glycosyltransferases differentially expressed in PDX defined a glyco-signature, whose prognostic value was validated on datasets including resected whole tumor tissues. The glyco-signature was able to discriminate three clusters of PDAC patients on the validation cohorts, two clusters displaying a short overall survival compared to one cluster having a better prognosis. Both poor prognostic clusters having different glyco-profiles in Puleo patient's cohort were correlated with stroma activated or desmoplastic subtypes corresponding to distinct microenvironment features (p-value < 0.0001). Besides, differential expression and enrichment analyses revealed deregulated functional pathways specific to different clusters. Interpretation: This study identifies a glyco-signature relevant for a prognostic use, potentially applicable to resected and unresectable PDAC. Furthermore, it provides new potential therapeutic targets. Funding: This work was supported by INCa (Grants number 2018-078 and 2018-079), Fondation ARC (Grant number ARCPJA32020070002326), Cancéropôle PACA, DGOS (labelization SIRIC, Grant number 6038), Amidex Foundation and Ligue Nationale Contre le Cancer and by institutional fundings from INSERM and the Aix-Marseille Université.
Document type :
Journal articles
Complete list of metadata

https://www.hal.inserm.fr/inserm-03411913
Contributor : Eric MAS Connect in order to contact the contributor
Submitted on : Tuesday, November 2, 2021 - 4:14:44 PM
Last modification on : Friday, April 1, 2022 - 3:48:08 AM
Long-term archiving on: : Thursday, February 3, 2022 - 7:31:33 PM

File

1-s2.0-S2352396421003340-main....
Publication funded by an institution

Identifiers

Collections

Citation

yousra Mohamed Abd-El-Halim, Abdessamad El Kaoutari, Françoise Silvy, Marion Rubis, Martin Bigonnet, et al.. A glycosyltransferase gene signature to detect pancreatic ductal adenocarcinoma patients with poor prognosis. EBioMedicine, Elsevier, 2021, 71, pp.103541. ⟨10.1016/j.ebiom.2021.103541⟩. ⟨inserm-03411913⟩

Share

Metrics

Record views

40

Files downloads

18